Bank of America Securities Maintained a Buy Rating on Merus N.V (MRUS)

Merus N.V. (NASDAQ:MRUS) is one of the Best All-Time High Stocks to Buy According to Analysts. On June 10, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Merus N.V. (NASDAQ:MRUS), with a $92 price target.

The analyst noted that a key trial is the ongoing Phase 2 study of Petosemtamab for metastatic colorectal cancer. This trial focuses on different groups of patients with specific genetic types who have not had EGFR treatment before. Ahmad noted that this step-by-step approach would enable the company to better identify responsive patients and is crucial due to the sizable market potential of metastatic colorectal cancer.

Moreover, the treatment works by targeting two molecules, EGFR and LGR5, which allows the drug to fight cancer stem cells. In addition to this, the company is also moving forward with a Phase 3 trial for Petosemtamab in head and neck squamous cell carcinoma. The analyst noted that the interim results suggest that the treatment has the potential to become first in line.

Merus N.V. (NASDAQ:MRUS) is a biotechnology company based in the Netherlands. The company focuses on creating advanced cancer treatments using its unique Multiclonics technology.

While we acknowledge the potential of MRUS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.